196 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Novel approach of fragment-based lead discovery applied to renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Discovery of highly potent renin inhibitors potentially interacting with the S3' subsite of renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Pharma
trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Pharma
Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Institutes For Biomedical Research
Inhibitors of฿-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Amgen
Novel BACE1 inhibitors with a non-acidic heterocycle at the P1' position.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kyoto Pharmaceutical University
The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Institutes For Biomedical Research
Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Daiichi Sankyo
Lead optimization of 5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxyhexanamides to reduce a cardiac safety issue: discovery of DS-8108b, an orally active renin inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Daiichi Sankyo
ß-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
F. Hoffmann-La Roche
The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Pharma
A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Pharma
Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogues on plasma renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sanofi Recherche
An integrated computational workflow for efficient and quantitative modeling of renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sanofi Us
Design and discovery of new (3S,5R)-5-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]piperidine-3-carboxamides as potent renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Daiichi Sankyo
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universite£
Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
National Hellenic Research Foundation
Design and optimization of novel (2S,4S,5S)-5-amino-6-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)-4-hydroxy-2-isopropylhexanamides as renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Daiichi Sankyo
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Design and synthesis of potent, isoxazole-containing renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Centre For Therapeutic Research
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Florida
Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Actelion Pharmaceuticals
Non-peptide renin inhibitors containing 2-(((3-phenylpropyl)phosphoryl)oxy)alkanoic acid moieties as P2-P3 replacements.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
E. Merck Darmstadt
Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Highly potent, orally active diester macrocyclic human renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Parke-Davis Pharmaceutical Research Division of Warner-Lambert
Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
Determination of dissociation constants of high affinity (pM) human renin inhibitors: application to analogues of ditekiren (U-71,038).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Upjohn Laboratories
Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Sharp and Dohme Research Laboratories
Substrate analogue renin inhibitors containing replacements of histidine in P2 or isosteres of the amide bond between P3 and P2 sites.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
E. Merck Darmstadt
Novel inhibitors of human renin. Cyclic peptides based on the tetrapeptide sequence Glu-D-Phe-Lys-D-Trp.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ici Pharmaceuticals Group
Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Renin inhibitory peptides. A beta-aspartyl residue as a replacement for the histidyl residue at the P-2 site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Upjohn
Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kissei Pharmaceutical
Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Wisconsin-Madison
Azido glycols: potent, low molecular weight renin inhibitors containing an unusual post scissile site residue.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Synthesis and renin inhibitory activity of angiotensinogen analogues having dehydrostatine, Leu psi [CH2S]Val, or Leu psi [CH2SO]Val at the P1-P1' cleavage site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Upjohn
Conformationally constrained renin inhibitory peptides: gamma-lactam-bridged dipeptide isostere as conformational restriction.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Upjohn
Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Upjohn
Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
alpha-Methylproline-containing renin inhibitory peptides: in vivo evaluation in an anesthetized, ganglion-blocked, hog renin infused rat model.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Design and synthesis of potent and specific renin inhibitors containing difluorostatine, difluorostatone, and related analogues.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydroxy-7-methyloctanoic acid.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Renin inhibitors. Substitution of the leucyl residues of Leu-Leu-Val-Phe-OCH3 with 3-amino-2-hydroxy-5-methylhexanoic acid.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
3,4-Diarylpiperidines as potent renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Center For Therapeutic Research
Discovery of pyrrolidine-basedß-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Centre For Therapeutic Research
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Centre For Therapeutic Research
Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Deutschland
Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sanofi-Aventis Deutschland
Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vitae Pharmaceuticals
Synthesis, biological evaluation and docking studies of octane-carboxamide based renin inhibitors with extended segments toward S3' site of renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Centre For Therapeutic Research
Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Gyeongsang National University (Gnu)
The discovery and synthesis of potent zwitterionic inhibitors of renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Centre For Therapeutic Research
Design and synthesis of aminohydantoins as potent and selective humanß-secretase (BACE1) inhibitors with enhanced brain permeability.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sanofi-Aventis Deutschland
Design and optimization of new piperidines as renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Actelion Pharmaceuticals
Identification of a new biaryl scaffold generating potent renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Center For Therapeutic Research
Addressing time-dependent CYP 3A4 inhibition observed in a novel series of substituted amino propanamide renin inhibitors, a case study.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Centre For Therapeutic Research
Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Frosst Centre For Therapeutic Research
Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Toyama
The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Nagasaki International University
Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Novel low molecular renin inhibitors which show good oral blood pressure lowering effects in marmosets![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Bioactive hydroxyethylene dipeptide isosteres with hydrophobic (P3-P1)-moieties. A novel strategy towards small non-peptide renin inhibitors![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Synthesis of α-hydroxy statine through a facially selective osmylation of a chiral α-amido crotonate![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Rational design, synthesis, and X-ray structure of renin inhibitors with extended P1 sidechains![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
The identification of a novel renin inhibitor of equivalent efficacy following oral or intravenous administration.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(→ P3)-P1' sites![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
MDL 74147, a novel selective and soluble inhibitor of human renin. Synthesis, structure-activity relationship, species and protease selectivities.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Conformationally restricted peptide isosteres. 2.1 Synthesis and in vitro potency of dipeptide renin inhibitors employing a 2-alkylsulfonyl-3-phenylcyclopropane carboxamide as a P3 amino acid replacement![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Mitsubishi Tanabe Pharma
Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Mitsubishi Tanabe Pharma
Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kalvista Pharmaceuticals
Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of ![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ucb
Re-emerging Aspartic Protease Targets: Examining ![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institute of Organic Chemistry and Biochemistry of The Czech Academy of Sciences
Rational design and synthesis of selective BACE-1 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Institutes For Biomedical Research
Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Annamalai University
Piperidine-renin inhibitors compounds with improved physicochemical properties.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
F. Hoffmann-La Roche
Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
F. Hoffmann-La Roche
Discovery of AM-6494: A Potent and Orally Efficacious ?-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-725![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Florida
Analyses of ligand binding in five endothiapepsin crystal complexes and their use in the design and evaluation of novel renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Time-resolved ligand exchange reactions: kinetic models for competitive inhibitors with recombinant human renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Boehringer Ingelheim Pharmaceuticals
alpha-Hydroxy phosphinyl-based inhibitors of human renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effects of structure on inhibition of pepsin and renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Inhibition of renin by substrate analogue inhibitors containing the olefinic amino acid 5(S)-amino-7-methyl-3(E)-octenoic acid.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Renin inhibitors based on novel dipeptide analogues. Incorporation of the dehydrohydroxyethylene isostere at the scissile bond.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Sharp & Dohme Research Laboratories
Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Analysis of structure-activity relationships in renin substrate analogue inhibitory peptides.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Renin inhibitors. Design of angiotensinogen transition-state analogues containing novel. (2R,3R,4R,5S)-5-amino-3,4-dihydroxy-2-isopropyl-7-methyloctanoic acid.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Synthesis and biological activity of some transition-state inhibitors of human renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ciba-Geigy
New human renin inhibitors containing an unnatural amino acid, norstatine.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kissei Pharmaceutical
Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Wisconsin
Renin inhibitors containing hydrophilic groups. Tetrapeptides with enhanced aqueous solubility and nanomolar potency.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Sharp & Dohme Research Laboratories
Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Renin inhibitors. Synthesis of transition-state analogue inhibitors containing phosphorus acid derivatives at the scissile bond.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ciba-Geigy Pharmaceuticals Division
Renin inhibitors containing isosteric replacements of the amide bond connecting the P3 and P2 sites.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
Renin inhibitors based on dipeptide analogues. Incorporation of the hydroxyethylene isostere at the P2/P3 sites.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Inhibitors of human renin. Cyclic peptide analogues containing a D-Phe-Lys-D-Trp sequence.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ici Pharmaceuticals Group
Thermodynamics of the interaction of inhibitors with the binding site of recombinant human renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Upjohn
Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ici Pharmaceuticals Group
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 1. Synthesis and biological properties of alkyl alcohol and statine derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ici Pharmaceuticals Group
New inhibitors of renin that contain novel phosphostatine Leu-Val replacements.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bioleap
Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in a human renin infused rat model and in conscious sodium-depleted monkeys.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Upjohn
1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 3.1 Synthesis and biological properties of aminodeoxystatine and difluorostatone derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ici Pharmaceuticals Group
New inhibitors of human renin that contain novel replacements at the P2 site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Sharp and Dohme Research Laboratories
Renin inhibitors containing C-termini derived from mercaptoheterocycles.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Sharp & Dohme Research Laboratories
C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbott Laboratories
1,2,3-trisubstituted cyclopropanes as conformationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Texas
Synthesis and use of 3-amino-4-phenyl-2-piperidones and 4-amino-2-benzazepin-3-ones as conformationally restricted phenylalanine isosteres in renin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Sharp and Dohme Research Laboratories
New modified heterocyclic phenylalanine derivatives. Incorporation into potent inhibitors of human renin.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth-Ayerst Research
Inhibitors of human renin with C-termini derived from amides and esters of alpha-mercaptoalkanoic acids.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Renin inhibitors containing new P1-P1' dipeptide mimetics with heterocycles in P1'.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
E. Merck Darmstadt
I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Neurogen
Neoglycopeptides as inhibitors of oligosaccharyl transferase: insight into negotiating product inhibition.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Massachusetts Institute of Technology